APLT — Applied Therapeutics Cashflow Statement
0.000.00%
- $56.45m
- -$22.95m
- $0.46m
- 14
- 15
- 44
- 13
Annual cashflow statement for Applied Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -94 | -106 | -82.5 | -120 | -106 |
Non-Cash Items | 10.6 | 15.5 | 13.3 | 66 | 18.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 5.15 | -0.614 | -8.84 | -1.44 | 2.52 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -78.2 | -90.7 | -78.1 | -55.2 | -84.3 |
Other Investing Cash Flow Items | -19.5 | 12.4 | 13.2 | 13.9 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -19.5 | 12.4 | 13.2 | 13.9 | 0 |
Financing Cash Flow Items | 2.52 | 4.43 | 3.1 | 1.55 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 136 | 74.7 | 27.7 | 74.5 | 114 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 38.6 | -3.58 | -37.2 | 33.2 | 29.5 |